Drug Approval | July 01, 2022
Lupin receives approval from USFDA for Paliperidone extended-release tablets
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
States have an important role in ensuring food safety and healthy food practices.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Subscribe To Our Newsletter & Stay Updated
